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In Vivo Bioluminescence Imaging To Evaluate Systemic and Topical
Antibiotics against Community-Acquired Methicillin-Resistant
Staphylococcus aureus-Infected Skin Wounds in Mice
Yi Guo,a Romela Irene Ramos,a John S. Cho,a Niles P. Donegan,b Ambrose L. Cheung,b Lloyd S. Millerc
Department of Medicine, Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, USAa; Department of
Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USAb; Department of Dermatology, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USAc
Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) frequently causes skin and soft tissue infections,
including impetigo, cellulitis, folliculitis, and infected wounds and ulcers. Uncomplicated CA-MRSA skin infections are typically
managed in an outpatient setting with oral and topical antibiotics and/or incision and drainage, whereas complicated skin infec-
tions often require hospitalization, intravenous antibiotics, and sometimes surgery. The aim of this study was to develop a
mouse model of CA-MRSA wound infection to compare the efficacy of commonly used systemic and topical antibiotics. A biolu-
minescent USA300 CA-MRSA strain was inoculated into full-thickness scalpel wounds on the backs of mice and digital photog-
raphy/image analysis and in vivo bioluminescence imaging were used to measure wound healing and the bacterial burden. Sub-
cutaneous vancomycin, daptomycin, and linezolid similarly reduced the lesion sizes and bacterial burden. Oral linezolid,
clindamycin, and doxycycline all decreased the lesion sizes and bacterial burden. Oral trimethoprim-sulfamethoxazole de-
creased the bacterial burden but did not decrease the lesion size. Topical mupirocin and retapamulin ointments both reduced
the bacterial burden. However, the petrolatum vehicle ointment for retapamulin, but not the polyethylene glycol vehicle oint-
ment for mupirocin, promoted wound healing and initially increased the bacterial burden. Finally, in type 2 diabetic mice, sub-
cutaneous linezolid and daptomycin had the most rapid therapeutic effect compared with vancomycin. Taken together, this
mouse model of CA-MRSA wound infection, which utilizes in vivo bioluminescence imaging to monitor the bacterial burden,
represents an alternative method to evaluate the preclinical in vivo efficacy of systemic and topical antimicrobial agents.
Community-acquired methicillin-resistant Staphylococcus au-reus (CA-MRSA) skin and soft tissue infections (SSTIs), such
as impetigo, folliculitis, cellulitis, and infected wounds and ulcers,
have been increasing for more than a decade and are creating a
serious public health concern (1, 2). In particular, outpatient and
emergency room visits for SSTIs have been estimated to result in
11.6 to 14.2 million ambulatory care visits per year in the United
States (3, 4). In 2004 and 2008, CA-MRSA was identified as the
most common cause (59%) of all SSTIs presenting to emergency
rooms across the United States (5, 6). In these and other studies,
the USA300 clone has been isolated in up to 90% of all CA-MRSA
SSTIs in the United States (5–8). USA300 causes severe and ne-
crotic SSTIs and often causes infections in otherwise healthy indi-
viduals without any known risk factors for infection (1, 2, 9).
Uncomplicated CA-MRSA SSTIs, such as impetigo, infected
abrasions, and folliculitis/furunculosis can be managed in an out-
patient setting with oral antibiotics and/or incision and drainage
(10–12). Typical oral antibiotic regimens used for CA-MRSA in-
fections include trimethoprim-sulfamethoxazole (TMP/SMX), a
tetracycline (doxycycline or minocycline), clindamycin or lin-
ezolid, and rifampin can be added as a second agent to these reg-
imens (10–12). Complicated CA-MRSA SSTIs such as deeper soft
tissue infections, surgical/traumatic wound infections, major ab-
scesses, cellulitis, and infected ulcers and burns require intrave-
nous antibiotics and sometimes surgical debridement (12, 13).
Commonly used intravenous antibiotics with coverage against
CA-MRSA include vancomycin, linezolid, daptomycin, telavan-
cin, clindamycin, tigecycline, and quinupristin-dalfopristin (12–
14). Topical antibiotics can also play an adjunctive role in CA-
MRSA SSTIs, including impetigo, infected abrasions/lacerations,
infections with poor blood supply (i.e., diabetic foot ulcers) and in
the prevention of postsurgical wound infections (1, 10, 11).Mupi-
rocin is a commonly used topical antibiotic for the treatment of
CA-MRSA SSTIs (1, 10, 11) and is also used for decolonization of
S. aureus and MRSA nasal carriage (15). Retapamulin is a newer
prescription-strength topical antibiotic that can also be used to
treat S. aureus and MRSA SSTIs (1, 10, 16).
A preclinical animalmodel system is an important step to eval-
uate the efficacy of an antimicrobial agent before more extensive
studies are performed in human subjects. Previous animalmodels
to evaluate S. aureus/MRSA SSTIs include a tape-stripping model
(17, 18), a burned skin model (19–21), and a skin surgical/suture
wound (22–25). However, in these models, large numbers of an-
imals are required because animals need to be euthanized at vari-
ous time points after infection to evaluate the ex vivo bacterial
burden by performing traditional CFU counting. The aim of the
present study was to develop amousemodel of CA-MRSAwound
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infection using a newly generated USA300 strain that possesses a
stable bioluminescent construct to compare the efficacy of com-
monly used systemic and topical antibiotics.
MATERIALS AND METHODS
CA-MRSAbioluminescent strain.TheUSA300LAC::luxbioluminescent
CA-MRSA strain, derived from the USA300 LAC parent strain, was used
in all experiments (26). USA300 LAC::lux possesses amodified luxABCDE
operon from the bacterial insect pathogen Photorhabdus luminescens,
which was chromosomally transduced from the Xen29 bioluminescent S.
aureus strain (Caliper, Perkin-Elmer Company, Alameda, CA) (27). This
resulted in a bioluminescent USA300 LAC::lux strain that constitutively
emits a blue-green light with a maximal emission wavelength of 490 nm
(only live and metabolically active bacteria will emit light). The biolumi-
nescent construct is stably integrated into the bacterial chromosome and
is maintained in all progeny without selection.
Preparation of bacteria for inoculation. USA300 LAC::lux bacteria
were streaked onto tryptic soy agar plates (tryptic soy broth [TSB] plus
1.5%Bacto agar [BD Biosciences, Franklin Lakes, NJ]) and grown at 37°C
overnight (28). Single bacterial colonies were cultured in TSB and grown
overnight at 37°C in a shaking incubator (MaxQ 4450; Thermo Fisher
Scientific,Waltham,MA).Mid-logarithmic-phase bacteria were obtained
after a 2-h subculture of a 1/50 dilution of the overnight culture. Bacteria
were pelleted, resuspended, and washed three times in phosphate-buff-
ered saline (PBS). Bacterial inocula (2 105 CFU, 2 106 CFU, or 2
107 CFU in 10 l of PBS) were estimated by measuring the absorbance at
600 nm (Biomate 3; Thermo Fisher Scientific). CFUwere verified after an
overnight culture.
Mice. Six-week-old male C57BL/6 mice were obtained from Jackson
Laboratories (Bar Harbor, ME). In some experiments, 12-week-old
NONcNZO10/LtJ male mice (Jackson Laboratories) on a 10 to 11% (wt/
wt) chowdiet (LabDiet 5k20; PMINutrition International, St. Louis,MO)
were used (29). NONcNZO10/LtJ male mice by 10 weeks of age develop a
disease closely mimicking human type 2 diabetes with visceral obesity,
hyperglycemia, dyslipidemia,moderate liver steatosis, and pancreatic islet
atrophy (29) and were confirmed to have hyperglycemia (blood glucose
levels  300 mg/dl) before they were used in experiments. Mice were
housed in one mouse per cage and in specific-pathogen-free conditions.
Mouse model of CA-MRSA skin wound infection using in vivo bio-
luminescence imaging. All procedures were approved by the UCLA An-
imal Research Committee. Mice were anesthetized with inhalation isoflu-
rane (2%), the posterior upper backswere shaved and three parallel 8-mm
linear full-thickness scalpel cuts (#11 blade) were made through the der-
mis (28). The wounds were subsequently inoculated with USA300 LAC::
lux (2 105 CFU, 2 106 CFU, or 2 107 CFU in 10 l of PBS) using a
micropipette. To obtain measurements of wound sizes, mice were anes-
thetized with inhalation isoflurane (2%) at several different time points
after infection (e.g., days 0, 1, 3, 5, 7, and 10) and digital photographs of
the infected-skin wounds were taken. The total lesion size (cm2) was
quantified by using the image analysis software program ImageJ (NIH
Research Services Branch [http://rsbweb.nih.gov/ij/]) and a millimeter
ruler as a reference. A measurement of bacterial burden was obtained by
performing in vivo bioluminescence imaging at the same time points us-
ing the Lumina II imaging system (Caliper). In vivo bioluminescence im-
aging data are presented on a color-scale overlaid on a grayscale photo-
graph of mice and quantified as total flux (photons/s) within a circular
region of interest using Living Image software (Caliper). In some experi-
ments, to confirm that the in vivo bioluminescent signals accurately rep-
resented the bacterial burden in vivo, CFU counts were determined after
overnight cultures of homogenized (Pro200 Series homogenizer; Pro Sci-
entific, Oxford, CT) 8-mmpunch biopsy specimens of lesional skin taken
at 4 h and on days 1, 3, 5, and 7 after inoculation. Typically, 5 to 10 mice
per group were used, and the numbers of mice used in each experiment
are indicated in the figure legends.
Subcutaneous and oral antibiotic therapy. Based on previously pub-
lished studies,micewere administered subcutaneous (to the flank skin) or
oral (via gavage) therapeutic doses of vancomycin (110 mg/kg adminis-
tered subcutaneously twice daily) (30, 31) (Novaplus; Hospira, Inc., Lake
Forest, IL), daptomycin (50 mg/kg administered subcutaneously daily)
(32, 33) (Cubicin; Cubist Pharmaceuticals, Inc., Lexington, MA), lin-
ezolid (60 mg/kg administered subcutaneously and orally twice daily)
(34) (Zyvox; Pfizer, Inc., NewYork,NY), clindamycin (100mg/kg admin-
istered orally three times a day) (35, 36) (Cleocin phosphate; Pfizer, Inc.),
doxycycline (100 mg/kg orally twice daily) (33), and TMP-SMX (320/
1,600 mg/kg administered orally twice daily) (37, 38). Linezolid was used
at the same dose for subcutaneous and oral administration because of
equivalent bioavailability when given via either route (39). These doses
were chosen to approximate the free-drug area under the curve (AUC) of
typical human doses of intravenous vancomycin (440 g·h/ml for 1 g
twice daily) (40), intravenous daptomycin (598 g·h/ml for 6 mg/kg
daily) (41), intravenous/oral linezolid (138 g·h/ml for 600 mg/kg twice
daily) (42), clindamycin (116g·h/ml for 600 mg three times a day) (33),
and doxycycline (55.7g·h/ml for 100mg twice daily) (43). All mice were
treated with the first dose of antibiotics administered at 4 h after CA-
MRSA inoculation and continued at the aforementioned regimens for 7
days. For the USA300 LAC::lux strain, the followingMICs weremeasured
according to established guidelines andmethods (44) using in-house pre-
pared broth microdilution trays: oxacillin, 16 g/ml; vancomycin, 1.0
g/ml; daptomycin, 0.25 g/ml; linezolid, 2.0 g/ml; clindamycin,
0.5 g/ml; doxycycline, 1.0 g/ml; and TMP/SMX, 0.5/9.5
g/ml.
Topical antibiotic therapy. CA-MRSA-infected skin wounds were
treated topically by applying 100 l of mupirocin 2% ointment (Bactro-
ban; GlaxoSmithKline, Research Triangle Park, NC), retapamulin 1%
ointment (Altabax; Stiefel/GlaxoSmithKline), or the corresponding vehi-
cle ointments (polyethylene glycol [mupirocin] andwhite petrolatum [re-
tapamulin]) at 4 h after CA-MRSA inoculation, followed by twice daily
(every 12 h) thereafter for a total of 7 days.
Statistical analysis. Data were compared using Student’s t test (two-
tailed). All data are expressed as mean the standard error of the mean
(SEM). Values of P 0.05 were considered statistically significant.
RESULTS
In vivo bioluminescence imaging to measure bacterial burden.
To model a CA-MRSA wound infection in mice, scalpel cuts on
the shaved backs ofmice were inoculated with the bioluminescent
USA300 LAC::lux strain (26). The wound lesion sizes (Fig. 1A and
B) and in vivo bacterial burden (Fig. 1C and D) of anesthetized
mice were determined by analyzing digital photographs of the
mice using image analysis (ImageJ; NIH Research Services
Branch) andmeasuring theUSA300 LAC::lux bioluminescent sig-
nals (Lumina II imaging system; Caliper), respectively. As a first
step, the optimal bacterial inoculum that produced a consistent
wound infection was determined by evaluating different inocula
ofUSA300 LAC::lux (2 105, 2 106, and 2 107CFUper 10l)
or no bacterial inoculation (none) (Fig. 1). The inoculum of 2
107 CFU induced the largest lesions and the 2 106 CFU induced
intermediate lesion sizes, which were both statistically greater
than those of uninfectedmice (Fig. 1A and B). In contrast, 2 105
CFU induced lesions that did not significantly differ from unin-
fected mice. The inoculum of 2 107 CFU induced higher biolu-
minescent signals than the 2  106 CFU, but the signals of both
inocula decreased over time (Fig. 1C andD). The inoculumof 2
105 CFU resulted in bioluminescent signals that were below the
bioluminescent signals of the other inocula and reached back-
ground levels by day 7. All three inocula had bioluminescent sig-
nals on days 1 through 5 that were statistically greater than the
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background bioluminescent signals of uninfected mice. Since our
ultimate goal was to produce a CA-MRSA wound infection that
induced relatively small lesion sizes and bioluminescent signals
that were greater than the uninfected wounds, the intermediate
inoculum of 2 106 CFUwas used in all subsequent experiments.
Correlation of in vivo bioluminescent signals with ex vivo
bacterial burden. To evaluate whether bioluminescent signals of
USA300 LAC::lux accurately represented the bacterial burden, in
vivo bioluminescence imaging and skin biopsies from the infected
wounds were performed on the same mice after inoculation with
2 106 CFU of USA300 LAC::lux. At 4 h and on days 1, 3, 5, and
7 after inoculation, the bioluminescent signals were 9.56 1.55
105, 1.72 0.07 105, 1.05 0.17 105, 5.0 0.37 104, and
2.84  0.18  104 photons/s (see Fig. S1A in the supplemental
material) and the ex vivo bacterial burden was 1.29 0.21 107,
2.95  0.34  106, 2.29  0.40  106, 2.7  0.42  105, and
2.97  0.78  104 CFU (see Fig. S1B in the supplemental mate-
rial), respectively. These in vivo bioluminescent signals highly cor-
related with the ex vivo CFU values (correlation coefficient R2 
0.9996) (Fig. 2). These data indicate that in vivo bioluminescence
imaging of wounds infected with USA300 LAC::lux provides an
accurate measurement of the in vivo bacterial burden that can be
measured noninvasively and longitudinally during the course of
an infection. It should be noted that the culture plates used to
FIG 1 Mousemodel of CA-MRSAwound infection. Three 8mm in length, parallel, full-thickness scalpel wounds on the backs of C57BL/6mice were inoculated with
2 105, 2 106, or 2 107 CFUof the bioluminescent CA-MRSA strain, USA300 LAC::lux, or no bacteria (none)/10l (n 5mice per group). (A)Mean total lesion
size (cm2) the standard error of themean (SEM). (B) Representative photographs of the lesions of the entire dorsal back (upper panels) and close-up photographs of
the lesions (lower panels) are shown. (C)Bacterial counts asmeasuredby in vivobioluminescence imaging (mean total flux [photons/s] the SEM) (logarithmic scale).
(D) Representative in vivo bioluminescent signals on a color scale overlaid on top of a grayscale image of mice. *, P  0.05; †, P  0.01; ‡, P  0.001 (USA300
LAC::lux-infectedmice versus none) (Student’s t test [two-tailed]).
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determine the CFUwere imaged to detect the presence or absence
of a bioluminescent signal. In every case, the CFU had a biolumi-
nescent signal (data not shown), indicating that vast majority of
bacteria present in the infected wounds were the bioluminescent
USA300 LAC::lux strain that were inoculated into these wounds
rather than other bacteria that may have contaminated the
wounds. Furthermore, the numbers of CFU at 4 h increased 6.5-
fold from the initial inoculum, demonstrating that the bacteria
were multiplying within the wound and that the infection was
established. We therefore chose to use the 4-h time point to initi-
ate antibiotic treatment of the CA-MRSA-infected skin wounds.
The 4-h time point was also the same time previously used to
initiate treatment of a topically applied mupirocin cream formu-
lation to treat a S. aureus surgical skin wound infection in mice
(23).
Efficacy of systemic (subcutaneous and oral) antibiotic ther-
apy. To evaluate the efficacy of commonly used intravenous anti-
biotics for hospitalized patients with complicated CA-MRSA
SSTIs (12), therapeutic doses in mice of vancomycin (110 mg/kg
twice daily) (30, 31), daptomycin (50 mg/kg daily) (32, 33), lin-
ezolid (60 mg/kg twice daily) (34), or sterile saline (sham control)
were administered subcutaneously beginning at 4 h after USA300
LAC::lux inoculation and continued at the above regimens
through day 7. We chose to evaluate daptomycin at a dose that
simulated the 6-mg/kg human dose, which is used to treat MRSA
bacteremia or complicated CA-MRSA SSTIs, rather than evaluat-
ing a dose that simulated the 4-mg/kg dose in humans, which is
typically used to treat uncomplicated CA-MRSA SSTIs (45). Mice
treated with vancomycin, daptomycin, or linezolid all had similar
lesion sizes compared with control mice until day 5. However, by
day 7, the antibiotic treatment groups had 40% significantly
decreased lesion sizes than sham control mice, demonstrating en-
hanced wound healing (Fig. 3A). The enhanced would healing
observed in the antibiotic treatment groups was associated with
significantly lower bioluminescent signals beginning on day 1 (up
to 7.6-fold decrease) and remained significantly below the signals
of sham control mice through day 7 (Fig. 3B). There were no
differences between the lesion sizes and bioluminescent signals
between the various antibiotic treatment groups. Taken together,
these data indicate that subcutaneously administered therapeutic
doses of vancomycin, daptomycin, and linezolid all resulted in
similar decreased lesion sizes and bioluminescent signals during a
CA-MRSA wound infection in mice.
To compare the efficacy of commonly used oral antibiotics that
are used for outpatient therapy of CA-MRSA SSTIs (12), clinda-
mycin (100mg/kg three times a day) (35, 36), linezolid (60 mg/kg
twice daily) (34), doxycycline (100mg/kg twice daily) (33), TMP-
SMX (320/1,600 mg/kg twice daily) (37, 38), or sterile saline
(sham control) were administered orally beginning at 4 h after
USA300 LAC::lux inoculation and continued as indicated through
day 7. Mice treated with oral linezolid had significantly decreased
lesion sizes comparedwith sham controlmice beginning on day 3,
whereas mice treated with clindamycin or doxycycline had signif-
icantly decreased lesion sizes beginning on day 5 (Fig. 3C and E).
TMP/SMX was the only oral antibiotic evaluated that did not
result in significantly decreased lesion sizes compared with sham
control mice (Fig. 3E). Oral linezolid had the most rapid thera-
peutic effect because it resulted in themost substantial decrease in
bioluminescent signals (8.3-fold on day 1), which was signifi-
cantly lower compared with the decreased bioluminescent signals
in mice treated with oral clindamycin (2.7-fold on day 1) (P 
0.05) (Fig. 3D). Oral TMP/SMX and doxycycline had biolumines-
cent signals that were decreased compared with sham control
mice beginning on day 3 after inoculation (3.0- and 2.6-fold on
day 3, respectively) (P 0.05) (Fig. 3F). After day 3, all of the oral
antibiotics resulted in bioluminescent signals that approached
background levels by days 5 to 7. In summary, these data indicate
that oral linezolid, clindamycin, and doxycycline, but not TMP/
SMX, resulted in decreased lesion sizes. In addition, all of these
oral antibiotics resulted in decreased bioluminescent signals with
linezolid having the most rapid therapeutic effect.
Efficacy of topical antibiotic therapy.Next, the efficacy of the
two Food and Drug Administration (FDA)-approved topical pre-
scription-strength ointments, mupirocin (1, 10, 11) and reta-
pamulin (1, 10, 16), were compared in this mouse model of CA-
MRSA wound infection. Mupirocin 2% ointment, retapamulin
1% ointment, or corresponding vehicle ointments (polyethylene
glycol [PEG; mupirocin] and white petrolatum [retapamulin])
were topically applied (100-l volume) to the infected wounds at
4 h after USA300 LAC::lux inoculation followed by twice daily
(every 12 h) for the next 7 days.Mupirocin ointment resulted in 29
to 58% decreased lesion sizes beginning at day 5 after inoculation
compared with the PEG vehicle ointment (Fig. 4B). In contrast,
retapamulin ointment resulted in lesion sizes that did not differ
frommice treated with petrolatum vehicle ointment alone. Com-
pared with their respective vehicle ointments, between days 1 and
5, mupirocin ointment resulted in a 5- to 12-fold significant re-
duction in bioluminescent signals, whereas retapamulin ointment
treatment resulted in a 10- to 41-fold significant reduction in bio-
luminescent signals (Fig. 4B). However, when the lesion sizes and
bioluminescent signals for the mupirocin and retapamulin oint-
ments were compared, they were not significantly different from
each other. Interestingly, the observed differences in effectiveness
of these ointments were impacted by changes induced by the ve-
hicle ointment alone. In particular, the petrolatum vehicle oint-
ment induced decreased lesion sizes that were comparable to
those of mice treated with mupirocin or retapamulin ointment.
This enhanced wound healing was unexpected because the petro-
FIG 2 In vivo bioluminescent signals of CA-MRSA-infected wounds highly
correlate with ex vivo bacterial CFU counts. Scalpel wounds on the backs of
micewere inoculatedwithUSA300 LAC::lux (2 106CFU/10l). Correlation
between in vivo bioluminescent signals (mean total flux [photons/s]  the
SEM) (logarithmic scale) from mice (n 6 per group) imaged at 4 h and on
days 1, 3, 5, and 7 and total ex vivo CFU (logarithmic scale) recovered from
8-mm lesional punch biopsies performed on euthanized mice (n  6 per
group) at the same time points. The trendline and the correlation coefficient of
determination (R2) between in vivo bioluminescent signals and total CFU are
shown.
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latum vehicle ointment also induced an increase in biolumines-
cent signals on day 1. In contrast, the PEG vehicle ointment had
lesion sizes or bioluminescent signals that were similar to those
observed without any topical treatment (saline control mice) in
Fig. 3.
Efficacy of systemic antibiotics in a mouse model of type 2
diabetes. One advantage of developing a mouse model of CA-
MRSA wound infection is that the efficacy of antibiotic therapy
can be evaluated in genetically engineered mouse strains that
mimic certain human diseases. One such disease is type II diabetes
in which patients develop chronic wounds and ulcers that can
become infected with CA-MRSA (46). To determine the efficacy
of antibiotic therapy against a CA-MRSA wound infection in a
mouse model of type II diabetes, the NONcNZO10/LtJ mouse
strain, which expresses six known obesity-induced diabetes quan-
titative trait loci, was used (29). NONcNZO10/LtJ male mice on a
high-fat diet developmany of the characteristics of type II diabetes
when they become 10 weeks of age, including visceral obesity,
hyperglycemia, dyslipidemia, moderate liver steatosis, and pan-
creatic islet atrophy (29). Vancomycin (110 mg/kg twice daily)
(30, 31), daptomycin (50 mg/kg daily) (32, 33), linezolid (60
mg/kg twice daily) (34), or sterile saline (sham control) were ad-
ministered subcutaneously to 12-week-old NONcNZO10/LtJ di-
abetic male mice beginning at 4-h after USA300 LAC::lux inocu-
lation and continued at the above regimens through day 7.
Although pharmacokinetic studies with vancomycin, daptomy-
FIG 3 Efficacy of systemic (subcutaneous and oral) antibiotics against CA-MRSA-infected wounds. Scalpel wounds on the backs of mice were inoculated with
USA300 LAC::lux (2 106 CFU/10l).Mice (n 5 to 10mice per group) were treated with subcutaneous vancomycin (110mg/kg twice daily), daptomycin (50
mg/kg once daily), linezolid (60mg/kg twice daily), or sterile saline (sham control) (top panels) or oral (via gavage) linezolid (60mg/kg twice daily), clindamycin
(100mg/kg three times a day), doxycycline (100mg/kg twice daily), TMP/SMX (320/1600mg/kg once daily), or sterile saline (sham control) (middle and bottom
panels). Antibiotic treatment was initiated at 4 h after CA-MRSA inoculation and continued for the first 7 days. (A, C, and E)Mean total lesion size (cm2) the
SEM. (B, D, and F) Bacterial counts as measured by in vivo bioluminescence imaging (mean total flux [photons/s] the SEM) (logarithmic scale). *, P 0.05;
†, P 0.01; ‡, P 0.001 (antibiotic treatment versus sham treatment [saline]) (Student’s t test [two-tailed]).
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cin, and linezolid were not performed on these diabetic mice,
these doses used were based on total body weight, which is how
vancomycin and daptomycin are dosed in humans and levels of
linezolid at normal dosing are decreased in obese patients (12, 47).
As expected, sham control NONcNZO10/LtJ mice developed
larger lesions and higher in vivo bioluminescent signals that per-
sisted longer (up to 14 days) compared with wild-type C57BL/6
mice used in Fig. 3 (Fig. 5). In NONcNZO10/LtJ mice, subcuta-
neously administered vancomycin resulted in significantly de-
creased lesion sizes on day 7 (22% decrease [P 0.05]), and sub-
cutaneously administered daptomycin and linezolid resulted in
significantly decreased lesion sizes on day 5 (19% [P 0.05] and
23% [P 0.05] decreases, respectively) and day 7 (38% [P 0.01]
and 44% [P  0.001] decreases, respectively) compared with
sham control mice (Fig. 5A). On day 1, vancomycin, daptomycin,
and linezolid resulted in 3.2-, 7.9-, and 13.9-fold significantly de-
creased bioluminescent signals compared with sham control mice
(Fig. 5B). The decreased bioluminescent signals in daptomycin-
and linezolid-treated mice were not statistically different from
each other. However, on day 1, the bioluminescent signals for
both daptomycin and linezolid were both significantly lower than
the bioluminescent signals of the vancomycin-treated mice (P 
0.05 and P 0.001, respectively). After day 1, vancomycin-, dap-
tomycin-, and linezolid-treated mice had similarly decreased bio-
luminescent signals compared with sham control mice. Taken to-
gether, in NONcNZO10/LtJ diabetic mice, subcutaneous
linezolid and daptomycin treatment had amore rapid therapeutic
effect compared with vancomycin, but after day 1, all three anti-
biotics had similar efficacy against this CA-MRSA wound infec-
tion.
DISCUSSION
CA-MRSA SSTIs represent a major public health threat in the
United States and are becoming an increasing problemworldwide
(1, 2, 13). Antimicrobial resistance among CA-MRSA isolates has
complicated the treatment of these infections. A rapid and cost-
effective preclinical animal model of CA-MRSA SSTIs could pro-
vide an alternative system to evaluate the in vivo efficacy of existing
and potential antimicrobial agents. In the present study, a mouse
model of a CA-MRSA skin wound infection was developed in
FIG 4 Efficacy of topical antibiotics against CA-MRSA-infected wounds. Scalpel wounds on the backs of mice were inoculated with USA300 LAC::lux (2 106
CFU/10 l). Mice (n 5 mice per group) were treated with topical mupirocin 2% ointment, retapamulin 1% ointment, or the corresponding vehicle ointment
(polyethylene glycol [mupirocin] and white petrolatum [retapamulin]). Antibiotic treatment was initiated at 4 h after CA-MRSA inoculation and continued
twice daily for the first 7 days. (A)Mean total lesion size (cm2) the SEM. (B) Bacterial counts as measured by in vivo bioluminescence imaging (mean total flux
[photons/s]  the SEM) (logarithmic scale). *, P  0.05; †, P  0.01; ‡, P  0.001 (antibiotic treatment versus sham treatment [saline]) (Student’s t test
[two-tailed]).
FIG 5 Efficacy of subcutaneous vancomycin, daptomycin, and linezolid against a CA-MRSA wound infection in diabetic mice. Scalpel wounds on the backs of
NONcNZO10/LtJ diabeticmice were inoculated withUSA300 LAC::lux (2 106 CFU/10l).Mice (n 5 to 10mice per group) were treated with subcutaneous
vancomycin (110 mg/kg twice daily), daptomycin (50 mg/kg once daily), linezolid (60 mg/kg twice daily), or sterile saline (sham control) beginning at 4 h after
CA-MRSA inoculation and continued for the first 7 days. (A) Mean total lesion size (cm2) the SEM. (B) Bacterial counts as measured by in vivo biolumines-
cence imaging (mean total flux [photons/s] the SEM) (logarithmic scale). *, P 0.05; †, P 0.01; ‡, P 0.001 (antibiotic treatment versus sham treatment
[saline]) (Student’s t test [two-tailed]).
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which a bioluminescent USA300 CA-MRSA strain (USA300
LAC::lux) was inoculated into skin wounds. Digital photography
and in vivo bioluminescence imaging were used to obtain nonin-
vasive and longitudinal measurements of wound healing and the
bacterial burden.
The bioluminescent USA300 LAC::lux strain used in the pres-
ent study has certain advantages compared with other available S.
aureus and CA-MRSA bioluminescent strains. First, this strain
was derived from the clinical USA300 LAC strain, which produces
toxins associated with the increased virulence of CA-MRSA, in-
cluding phenol soluble modulins, alpha-toxin, and Panton-Val-
entine leukocidin (48, 49). USA300 LAC::lux also possesses the
bioluminescent construct stably integrated into the bacterial
chromosome (26). Since the bioluminescent construct is main-
tained in all progeny without selection, it is thus not lost in vivo
over time (26). We demonstrated that the in vivo bioluminescent
signals of USA300 LAC::lux highly correlated with the numbers of
ex vivo CFU harvested from the same infected skin wounds at
various different time points (correlation coefficientR2 0.9996)
(Fig. 2). Thus, in vivo USA300 LAC::lux bioluminescent signals
provide an accurate measurement of bacterial burden that does
not require euthanasia of animals for traditional CFU counting to
determine the bacterial burden at each time point. For example,
only 5 to 10 mice per group were used to monitor the bacterial
burden with in vivo bioluminescence imaging. In contrast, to ob-
tain CFU data from the infected skin, at least 5 mice per group
would need to be euthanized at each time point (i.e., days 1, 3, 5,
and 7), corresponding to 20 total mice per group. For future stud-
ies that seek to utilize techniques of in vivo bioluminescence im-
aging to monitor the bacteria burden in other animal models of
infection, the bioluminescent construct containing the modified
luxABCDE operon, which was chromosomally induced from
Xen29 (Caliper, a Perkin-Elmer Company, Alameda, CA) (27),
could be transduced into other S. aureus and MRSA strains (50,
51). Although, the in vivo bioluminescent signals correlate with
bacterial burden, they are also dependent upon the transcription/
translation of the bioluminescent construct as well as the meta-
bolic activity of the bacteria (50, 51). However, we and others have
demonstrated that in vivo bioluminescence imaging can be used to
monitor the bacterial burden in various in vivomodels of biofilm
formation (26, 27, 52), demonstrating that this technology is sen-
sitive enough to detect low levels of light produced by bacteria in
biofilms.
This mouse model was used to compare the efficacy of com-
monly used systemic antibiotics against CA-MRSA SSTIs. We
found that subcutaneous administration of therapeutic doses of
vancomycin, daptomycin, or linezolid were all effective in treating
the CA-MRSA infection in mice, suggesting that these antibiotics
would have similar efficacy against CA-MRSA SSTIs in humans.
In addition, both subcutaneous linezolid and daptomycin had a
more rapid therapeutic effect in type II diabetic mice compared to
vancomycin, suggesting that linezolid and daptomycin might
have an additional clinical benefit in the context of diabetes. How-
ever, these preliminary results with these diabetic mice should be
interpreted with caution since detailed pharmacokinetics studies
were not performed on these mice, and the dosages used were
based on total body weight. Nonetheless, there have been studies
in humans that evaluated the efficacy of intravenous daptomycin
or linezolid as single agents comparedwith intravenous vancomy-
cin in the treatment of CA-MRSA SSTIs. In general, daptomycin
has been shown to have increased efficacy compared with vanco-
mycin (53). However, one study demonstrated that daptomycin
had similar efficacy compared with vancomycin in the treatment
of diabetic foot ulcers (54). Most studies have found that linezolid
has equivalent or superior efficacy compared with vancomycin
(55–60) and similar efficacy as vancomycin in diabetic patients
(57). Given these findings in humans, this mouse model was able
to confirm the efficacy of these antibiotics against a CA-MRSA
wound infection, but it was not able to recapitulate the potentially
increased efficacy of linezolid or daptomycin compared with van-
comycin in nondiabetic mice. The reason for this may be due to
different pharmacokinetics (i.e., absorption, distribution, metab-
olism, and elimination) between the species, which is a limitation
of preclinical animal models. Despite this drawback, we believe
that the ability to monitor wound healing and bacterial burden
longitudinally over time provides valuable preclinical informa-
tion about overall efficacy, which is necessary to establish before
the commencement of more comprehensive studies in humans.
Our findings involving the comparison of orally administered
antibiotics to treat the CA-MRSA wound infections in mice indi-
cated that linezolid, clindamycin, doxycycline, and TMP/SMX
were all effective in reducing the bacterial burden, but linezolid
had a more rapid therapeutic effect. The reason that the linezolid
resulted in a more dramatic decrease in bacterial burden than
clindamycin at day 1 after infection is not clear. As mentioned
above, this result could be due to different pharmacokinetics of
these antibiotics inmice.Nonetheless, it should bementioned that
inducible clindamycin resistance is found in up to 8.4% of CA-
MRSA strains, and this should be taken into account when treat-
ing patients (61). In this mousemodel, TMP/SMXwas effective at
reducing the bioluminescent signals at a high dose (320/1,600
mg/kg twice daily). However, TMP/SMXwas the only oral antibi-
otic evaluated that had no efficacy in decreasing the size of the
lesions. It should be mentioned that TMP/SMX at a lower dose
(160/800 mg twice daily) had no efficacy in decreasing the lesion
size or bioluminescent signals (data not shown), even though this
strain was highly sensitive to this drug (MIC  0.5 g/ml). The
high dose of TMP/SMX that was required for efficacy in this
mouse model may be due the increased content of thymidine in
mouse sera and tissues, which interferes with the activity of TMP
(62). Since infected human tissuesmay also have increased thymi-
dine levels, some studies have used high doses of TMP/SMX in
treating CA-MRSA SSTIs in humans (37, 38).
Since this model of CA-MRSA SSTI involved the infection of
open skin wounds, it provided an opportunity to evaluate the
efficacy of topically applied antimicrobial agents. We compared
two FDA-approved prescription-strength topical ointments,
mupirocin 2% ointment and retapamulin 1% ointment. We
found that both mupirocin and retapamulin ointments were
equally effective in reducing the bacterial burden to levels seen
with the subcutaneously and orally administered antibiotics. In-
terestingly, the white petrolatum ointment, the vehicle for reta-
pamulin, initially induced an increase in the bacterial burden,
which was not observed with PEG vehicle ointment for mupiro-
cin. Despite this higher bacterial burden, the petrolatumointment
resulted in faster wound healing and the wound sizes were virtu-
ally identical to those treated with the mupirocin or retapamulin
ointments. Therefore, the petrolatum vehicle ointment may pro-
vide a therapeutic benefit compared with the PEG vehicle oint-
ment because it promoted wound healing. Clearly, the choice of
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vehicle is an important consideration in the development of fu-
ture topical antimicrobial therapies. It could be that a vehicle that
enhances wound healing without affecting bacterial growth may
be even more efficacious.
One limitation of our study is that we studied a single isolate of
USA300 CA-MRSA and the virulence and antibiotic therapeutic
effects may be different with otherMRSA strains. Moreover, since
we only evaluated the USA300 strain, we were not able to describe
variability between strains, including differences betweenUSA300
and USA100 strains, which are likely very different because
USA100 strains produce fewer toxins and may be less virulent
than USA300 strains. These limitations will require additional
studies to resolve.
Taken together, the mouse model of CA-MRSA wound infec-
tion developed here utilized digital photography/image analysis
and in vivo bioluminescence imaging to monitor wound healing
and the bacterial burden longitudinally over time. Since this
model does not require euthanasia to determine the bacterial bur-
den, fewer numbers of animals are required to evaluate the effi-
cacy of antimicrobial agents, which is an important consideration
for the reduction, refinement, and replacement of animals used in
research and testing. For this particular model, since the biolumi-
nescent signals for the antibiotic treatment and the sham control
groups were nearly identical by day 7, future experimentsmay not
need to be extended beyond day 5, providing additional labor and
experimental cost savings. Thismodel could serve as an alternative
or complementary noninvasive, cost-effective, and accurate pre-
clinical animal model to investigate in vivo efficacy of certain sys-
temic and topical antimicrobial agents before extensive studies in
human subjects. Our results using this model indicate that there
are several viable options for intravenous and oral antibiotic ther-
apy for the treatment of CA-MRSA SSTIs in humans and topical
antibiotic therapy may provide an additional therapeutic benefit.
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